DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)

company name or ticker

Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog

Gilead's HCV Combo Drug Harvoni Secures CHMP Backing - Analyst Blog

Prostate Cancer Incidence Is the Highest in These 5 States

Prostate cancer is the most diagnosed cancer type in the U.S., with nearly 239,000 new cases diagnosed in 2013. Find out what existing and developing pharmaceutical products are being used to improve patients' overall survival and quality of life and where the disease is most prominent.

Alnylam Starts New Study on Cardiac Amyloidosis Patients - Analyst Blog

MannKind and Sanofi Complete Afrezza Collaboration Deal - Analyst Blog

Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog

Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog

Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog

Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog

First Week of November 22nd Options Trading For Medivation (MDVN)

See More Articles...